On April 15, the U.S. Food and Drug Administration (FDA) approved Corlanor (ivabradine) for use in patients with chronic heart failure who have stable symptoms, a resting heart rate of at least 70 beats per minute, and who are also taking beta blockers. In clinical trials, Corlanor reduced the time to the first occurrence of hospitalization in patients with worsening heart failure by decreasing overall heart rate. Common side effects include bradycardia, hypertension, atrial fibrillation and temporary vision disturbance.

The new drug was reviewed under the FDA’s priority review program and was also granted fast track designation. Corlanor is the first approved product in this drug class. Read more in the FDA’s announcement.

Keywords: Adrenergic beta-Antagonists, Atrial Fibrillation, Benzazepines, Bradycardia, Heart Failure, Heart Rate, Hospitalization, Hypertension, United States Food and Drug Administration

< Back to Listings